Table of Contents
GSK chair Sir Jonathan Symonds gave the keynote address at the Jefferies Global Healthcare Conference in London on Monday, November 16, 2026, in conversation with Jefferies president Brian Friedman. Symonds, AstraZeneca’s finance chief at the time, said its 2007 purchase of MedImmune carried “a premium on a premium” and was the most difficult and painful deal of the AstraZeneca and Novartis years.
Lessons from a demerger
Symonds said ICI’s 1993 demerger of the business that became Zeneca, on which Symonds worked as an accountant, shaped much of the career that followed. Symonds recalled saying at the time that the residual chemical business would not succeed. ICI was acquired by AkzoNobel in 2008. “The bit that’s left after a de-merger, which is where all the challenges are,” Symonds said.
Zeneca to AstraZeneca
Symonds became Zeneca’s finance director in 1997, taking the job, as Friedman put it, knowing the company might be acquired and that it might not be a 10-year opportunity. Within 18 months, Symonds said, Zeneca was negotiating a merger; Astra and Zeneca merged in 1999. Symonds named Syngenta, formed in 2000 from the agribusinesses of AstraZeneca and Novartis, as probably the deal Symonds is most proud of.
Symonds said the decision to join came down to Zeneca’s chief executive, Sir David Barnes, “a man of the highest integrity”. “I think that was the best decision I ever made in my career,” Symonds said.
The pharma mergers of that era rested on two kinds of scale, Symonds said: the sales forces needed for US primary care, and scale in R&D, where the bet was that bigger compound libraries would win. “It was gonna be a land grab. And eventually, eventually, innovation would be industrialised,” Symonds said, adding that this has since been proven wrong.
Goldman Sachs
Symonds said David Brennan and Symonds were the two candidates to become AstraZeneca’s chief executive, and that the two were great friends then and still are. Symonds recalled telling Lloyd Blankfein, then Goldman Sachs chief executive: “I want to do the hardest thing I could possibly do. It had to be different. And it had to be difficult.”
Symonds joined Goldman and stayed through the financial crisis, but said the move ended partly because “once you’d been used to taking decisions and taking accountability, I wasn’t really a good advisor.”
“A premium on a premium”
Asked by Friedman how many of the deals from the AstraZeneca and Novartis years would be worth doing again, Symonds said: “I’d actually say most.”
AstraZeneca agreed to buy MedImmune in April 2007 for about $15.6 billion. “There was a premium on it. There was a premium on a premium,” Symonds said.
Symonds recalled telling Brennan: “we’ve got to do this. Not almost at any price, but we have to do this”. Symonds described MedImmune as the last free-standing, fully developed business with everything from pipeline to protein engineering to manufacturing, and said industrial logic and the business case are “what I always look for first”.
Novartis and the sum of the parts
At Novartis, Symonds worked with Daniel Vasella, then chairman, whom Symonds called “one of the most charismatic people that you would ever meet” and “inspirational, capable of building a big, big vision, bold, brave”, though tough to work with.
Symonds said AstraZeneca had spun off businesses too quickly in the push to become a pure pharma company, without realising the need for a relatively stable pipeline, and that three almost consecutive failures nearly brought the company down. Symonds therefore valued a mix of businesses whose risks did not work against each other, provided each had intrinsic value. “The whole had to be greater than the sum of the parts,” Symonds said.
Applying cash-flow returns, Symonds said, showed the Novartis portfolio might be a good defensive strategy but “It is not value adding”. Symonds said the Alcon and Sandoz spin-offs have done well, and that the vaccines business Novartis sold to GSK fits well in the GSK portfolio.
About GSK
Symonds has chaired GSK since September 2019, a period in which GSK spun off its consumer healthcare business, Haleon.
Onyx also reported from the conference on EyePoint’s DURAVYU program.
Sources: Keynote address, “A Conversation Between Sir Jonathan Symonds and Brian Friedman”, Jefferies Global Healthcare Conference in London, November 16, 2026; GSK board biography; Jefferies conference page; AstraZeneca/MedImmune deal coverage, PharmaTimes (April 23, 2007)
Coming up: Cell & Gene Leaders Live, Sun 15 Nov at The Shard · London Life Sciences Week Guide, 15–19 Nov 2026 ·


Comments